PLoS ONE (Jan 2021)

Demographic, clinical, and epidemiologic characteristics of persons under investigation for Coronavirus Disease 2019-United States, January 17-February 29, 2020.

  • Olivia L McGovern,
  • Mark Stenger,
  • Sara E Oliver,
  • Tara C Anderson,
  • Cheryl Isenhour,
  • Matthew R Mauldin,
  • Nia Williams,
  • Eric Griggs,
  • Tonny Bogere,
  • Chris Edens,
  • Aaron T Curns,
  • Joana Y Lively,
  • Yingtao Zhou,
  • Songli Xu,
  • Maureen H Diaz,
  • Jessica L Waller,
  • Kevin R Clarke,
  • Mary E Evans,
  • Elisabeth M Hesse,
  • Sapna Bamrah Morris,
  • Robert P McClung,
  • Laura A Cooley,
  • Naeemah Logan,
  • Andrew T Boyd,
  • Allan W Taylor,
  • Kristina L Bajema,
  • Stephen Lindstrom,
  • Christopher A Elkins,
  • Christopher Jones,
  • Aron J Hall,
  • Samuel Graitcer,
  • Alexandra M Oster,
  • Alicia M Fry,
  • Marc Fischer,
  • Laura Conklin,
  • Runa H Gokhale

DOI
https://doi.org/10.1371/journal.pone.0249901
Journal volume & issue
Vol. 16, no. 4
p. e0249901

Abstract

Read online

BackgroundThe Coronavirus Disease 2019 (COVID-19) pandemic, caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), evolved rapidly in the United States. This report describes the demographic, clinical, and epidemiologic characteristics of 544 U.S. persons under investigation (PUI) for COVID-19 with complete SARS-CoV-2 testing in the beginning stages of the pandemic from January 17 through February 29, 2020.MethodsIn this surveillance cohort, the U.S. Centers for Disease Control and Prevention (CDC) provided consultation to public health and healthcare professionals to identify PUI for SARS-CoV-2 testing by quantitative real-time reverse-transcription PCR. Demographic, clinical, and epidemiologic characteristics of PUI were reported by public health and healthcare professionals during consultation with on-call CDC clinicians and subsequent submission of a CDC PUI Report Form. Characteristics of laboratory-negative and laboratory-positive persons were summarized as proportions for the period of January 17-February 29, and characteristics of all PUI were compared before and after February 12 using prevalence ratios.ResultsA total of 36 PUI tested positive for SARS-CoV-2 and were classified as confirmed cases. Confirmed cases and PUI testing negative for SARS-CoV-2 had similar demographic, clinical, and epidemiologic characteristics. Consistent with changes in PUI evaluation criteria, 88% (13/15) of confirmed cases detected before February 12, 2020, reported travel from China. After February 12, 57% (12/21) of confirmed cases reported no known travel- or contact-related exposures.ConclusionsThese findings can inform preparedness for future pandemics, including capacity for rapid expansion of novel diagnostic tests to accommodate broad surveillance strategies to assess community transmission, including potential contributions from asymptomatic and presymptomatic infections.